Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Predictive factors for response to salvage stereotactic body radiotherapy in oligorecurrent prostate cancer limited to lymph nodes: a single institution experience.

Oehler C, Zimmermann M, Adam L, Curschmann J, Sumila M, Strebel RT, Cathomas R, Li Q, Schneider U, Zwahlen DR.

BMC Urol. 2019 Sep 9;19(1):84. doi: 10.1186/s12894-019-0515-z.

2.

Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy.

De Bleser E, Jereczek-Fossa BA, Pasquier D, Zilli T, Van As N, Siva S, Fodor A, Dirix P, Gomez-Iturriaga A, Trippa F, Detti B, Ingrosso G, Triggiani L, Bruni A, Alongi F, Reynders D, De Meerleer G, Surgo A, Loukili K, Miralbell R, Silva P, Chander S, Di Muzio NG, Maranzano E, Francolini G, Lancia A, Tree A, Deantoni CL, Ponti E, Marvaso G, Goetghebeur E, Ost P.

Eur Urol. 2019 Jul 19. pii: S0302-2838(19)30533-0. doi: 10.1016/j.eururo.2019.07.009. [Epub ahead of print]

PMID:
31331782
3.

Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy.

Ponti E, Lancia A, Ost P, Trippa F, Triggiani L, Detti B, Ingrosso G.

Eur Urol Focus. 2017 Dec;3(6):538-544. doi: 10.1016/j.euf.2017.07.006. Epub 2017 Aug 8.

PMID:
28801240
4.

Salvage Stereotactic Body Radiotherapy for Isolated Lymph Node Recurrent Prostate Cancer: Single Institution Series of 94 Consecutive Patients and 124 Lymph Nodes.

Jereczek-Fossa BA, Fanetti G, Fodor C, Ciardo D, Santoro L, Francia CM, Muto M, Surgo A, Zerini D, Marvaso G, Timon G, Romanelli P, Rondi E, Comi S, Cattani F, Golino F, Mazza S, Matei DV, Ferro M, Musi G, Nolè F, de Cobelli O, Ost P, Orecchia R.

Clin Genitourin Cancer. 2017 Aug;15(4):e623-e632. doi: 10.1016/j.clgc.2017.01.004. Epub 2017 Jan 11.

PMID:
28185875
5.

Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years.

Suardi N, Gandaglia G, Gallina A, Di Trapani E, Scattoni V, Vizziello D, Cucchiara V, Bertini R, Colombo R, Picchio M, Giovacchini G, Montorsi F, Briganti A.

Eur Urol. 2015 Feb;67(2):299-309. doi: 10.1016/j.eururo.2014.02.011. Epub 2014 Feb 18.

PMID:
24571959
6.

Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography.

Rigatti P, Suardi N, Briganti A, Da Pozzo LF, Tutolo M, Villa L, Gallina A, Capitanio U, Abdollah F, Scattoni V, Colombo R, Freschi M, Picchio M, Messa C, Guazzoni G, Montorsi F.

Eur Urol. 2011 Nov;60(5):935-43. doi: 10.1016/j.eururo.2011.07.060. Epub 2011 Aug 3.

PMID:
21840116
7.

Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study.

Steuber T, Jilg C, Tennstedt P, De Bruycker A, Tilki D, Decaestecker K, Zilli T, Jereczek-Fossa BA, Wetterauer U, Grosu AL, Schultze-Seemann W, Heinzer H, Graefen M, Morlacco A, Karnes RJ, Ost P.

Eur Urol Focus. 2018 Mar 10. pii: S2405-4569(18)30077-4. doi: 10.1016/j.euf.2018.02.015. [Epub ahead of print]

PMID:
29530632
8.

Nodal Oligorecurrent Prostate Cancer: Anatomic Pattern of Possible Treatment Failure in Relation to Elective Surgical and Radiotherapy Treatment Templates.

De Bruycker A, De Bleser E, Decaestecker K, Fonteyne V, Lumen N, De Visschere P, De Man K, Delrue L, Lambert B, Ost P.

Eur Urol. 2019 May;75(5):826-833. doi: 10.1016/j.eururo.2018.10.044. Epub 2018 Nov 29.

PMID:
30503072
9.

Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy.

Berkovic P, De Meerleer G, Delrue L, Lambert B, Fonteyne V, Lumen N, Decaestecker K, Villeirs G, Vuye P, Ost P.

Clin Genitourin Cancer. 2013 Mar;11(1):27-32. doi: 10.1016/j.clgc.2012.08.003. Epub 2012 Sep 24.

PMID:
23010414
10.

68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy.

Farolfi A, Ceci F, Castellucci P, Graziani T, Siepe G, Lambertini A, Schiavina R, Lodi F, Morganti AG, Fanti S.

Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):11-19. doi: 10.1007/s00259-018-4066-4. Epub 2018 Jun 15.

PMID:
29905907
11.

Natural History of Clinical Recurrence Patterns of Lymph Node-Positive Prostate Cancer After Radical Prostatectomy.

Moschini M, Sharma V, Zattoni F, Quevedo JF, Davis BJ, Kwon E, Karnes RJ.

Eur Urol. 2016 Jan;69(1):135-42. doi: 10.1016/j.eururo.2015.03.036. Epub 2015 Apr 10.

PMID:
25865061
12.

Salvage Stereotactic Body Radiotherapy for Patients With Prostate Cancer With Isolated Lymph Node Metastasis: A Single-Center Experience.

Ponti E, Ingrosso G, Carosi A, Di Murro L, Lancia A, Pietrasanta F, Santoni R.

Clin Genitourin Cancer. 2015 Aug;13(4):e279-e284. doi: 10.1016/j.clgc.2014.12.014. Epub 2014 Dec 30.

PMID:
25604915
13.

Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.

Gandaglia G, Fossati N, Karnes RJ, Boorjian SA, Colicchia M, Bossi A, Seisen T, Cozzarini C, Di Muzio N, Noris Chiorda B, Zaffuto E, Wiegel T, Shariat SF, Goldner G, Joniau S, Battaglia A, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Montorsi F, Briganti A.

Eur Urol. 2018 Apr;73(4):512-518. doi: 10.1016/j.eururo.2017.11.020. Epub 2017 Dec 8.

PMID:
29229176
14.

Robotic salvage lymph node dissection for nodal-only recurrences after radical prostatectomy: Perioperative and early oncological outcomes.

Linxweiler J, Saar M, Al-Kailani Z, Janssen M, Ezziddin S, Stöckle M, Siemer S, Ohlmann CH.

Surg Oncol. 2018 Jun;27(2):138-145. doi: 10.1016/j.suronc.2018.02.010. Epub 2018 Feb 24.

PMID:
29937163
15.

The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.

Bianchi L, Nini A, Bianchi M, Gandaglia G, Fossati N, Suardi N, Moschini M, Dell'Oglio P, Schiavina R, Montorsi F, Briganti A.

Eur Urol. 2016 Jun;69(6):1142-8. doi: 10.1016/j.eururo.2015.12.010. Epub 2015 Dec 31.

PMID:
26749093
16.

Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences.

Ost P, Jereczek-Fossa BA, Van As N, Zilli T, Tree A, Henderson D, Orecchia R, Casamassima F, Surgo A, Miralbell R, De Meerleer G.

Clin Oncol (R Coll Radiol). 2016 Sep;28(9):e115-20. doi: 10.1016/j.clon.2016.04.040. Epub 2016 Apr 28.

PMID:
27133946
17.

Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation.

Kroeze SGC, Henkenberens C, Schmidt-Hegemann NS, Vogel MME, Kirste S, Becker J, Burger IA, Derlin T, Bartenstein P, Eiber M, Mix M, la Fougère C, Christiansen H, Belka C, Combs SE, Grosu AL, Müller AC, Guckenberger M.

Eur Urol Focus. 2019 Sep 5. pii: S2405-4569(19)30270-6. doi: 10.1016/j.euf.2019.08.012. [Epub ahead of print]

PMID:
31495759
19.

Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?

Goldstein J, Even-Sapir E, Ben-Haim S, Saad A, Spieler B, Davidson T, Berger R, Weiss I, Appel S, Lawrence YR, Symon Z.

Am J Clin Oncol. 2017 Jun;40(3):256-259. doi: 10.1097/COC.0000000000000139.

PMID:
25319322
20.

Toxicity and efficacy of salvage carbon 11-choline positron emission tomography/computed tomography-guided radiation therapy in patients with lymph node recurrence of prostate cancer.

Fodor A, Berardi G, Fiorino C, Picchio M, Busnardo E, Kirienko M, Incerti E, Dell'Oca I, Cozzarini C, Mangili P, Pasetti M, Calandrino R, Gianolli L, Di Muzio NG.

BJU Int. 2017 Mar;119(3):406-413. doi: 10.1111/bju.13510. Epub 2016 May 24.

Supplemental Content

Support Center